Acasă › Leucemie limfatică cronică › California

Studii clinice pentru Leucemie limfatică cronică în California

33 studii pentru Leucemie limfatică cronică caută participanți în California.

Orașe în California

Text oficial al studiului (în engleză)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Kaiser Permanente-Anaheim, Anaheim
Kaiser Permanente-Baldwin Park, Baldwin Park
Kaiser Permanente-Bellflower, Bellflower
și încă 12

În curs de recrutareFaza 3

Vârste de 65 ani și peste · Toate sexele · Actualizat 2 oct. 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
PCR Oncology, Arroyo Grande
AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
și încă 20

În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți

Vârste de la 40 la 75 · Toate sexele · Actualizat 2 oct. 2026 · NCT05334069

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Research Site, La Jolla

În curs de recrutareFaza 1/2

Vârste de 18 ani și peste · Toate sexele · Actualizat 30 sept. 2026 · NCT06542250

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Kaiser Permanente-Anaheim, Anaheim
Kaiser Permanente-Baldwin Park, Baldwin Park
Kaiser Permanente-Bellflower, Bellflower
și încă 28

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 30 sept. 2026 · NCT04269902

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

GC2202 Study Site 115, Huntington Park

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 30 sept. 2026 · NCT05645107

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Uci Health Laguna Hills, Laguna Hills
Chao Family Comprehensive Cancer Center, Orange
Stanford Cancer Institute, Palo Alto
și încă 1

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT06943872

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
Stanford Medicine, Palo Alto
UCLA Santa Monica Cancer Care, Santa Monica

În curs de recrutareFaza 1/2

Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT05006716

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

City of Hope National Medical Center, Duarte
Chao Family Comprehensive Cancer Center, Orange
Stanford Cancer Institute, Palo Alto

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT07277231

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

UCLA Department of Medicine Hematologyoncology, Los Angeles
Scripps Prebys Cancer Center, San Diego
Pih Health Whittier Hospital, Whittier

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT06846671

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Kaiser Permanente Southern California, Irvine
University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
Cancer and Blood Specialty Clinic, Los Alamitos
și încă 8

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT06973187

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

MemorialCare Health System - Long Beach Medical Center ( Site 5421), Long Beach

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 24 sept. 2026 · NCT05947851

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Moores Cancer Center ( Site 0003), La Jolla
Care Access - South Pasadena ( Site 0070), Pasadena

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 24 sept. 2026 · NCT06136559

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

UC Irvine, Orange

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 21 sept. 2026 · NCT07648264

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

City of Hope, Duarte
Cedars-Sinai Medical Center, Los Angeles
Scripps Health, San Diego

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 17 sept. 2026 · NCT07221500

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

City of Hope Comprehensive Cancer Center, Duarte
City of Hope at Irvine Lennar, Irvine
University of California Davis Comprehensive Cancer Center, Sacramento

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 11 sept. 2026 · NCT07061951

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

City of Hope National Medical Center, Duarte

În curs de recrutareFaza 1/2

Vârste de 12 ani și peste · Toate sexele · Actualizat 3 sept. 2026 · NCT04588922

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Pacific Cancer Medical Center, Inc, Anaheim
TOI Clinical Research, Cerritos
Stanford School of Medicine-Cancer Clinical Trials Office, Palo Alto

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 17 aug. 2026 · NCT05254743

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

City of Hope, Duarte

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 17 aug. 2026 · NCT06528301

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

City of Hope, Duarte
Valkyrie Clinical Trials, Los Angeles

În curs de recrutareFaza 1/2

Vârste de la 13 la 90 · Toate sexele · Actualizat 6 aug. 2026 · NCT06533579

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

City of Hope Medical Center, Duarte

În curs de recrutareFaza 1Voluntari sănătoși bineveniți

Vârste de la 18 la 75 · Toate sexele · Actualizat 28 iul. 2026 · NCT07020533

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte
University of California, San Francisco, San Francisco

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 2 iul. 2026 · NCT05131022

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco, San Francisco

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 22 iun. 2026 · NCT04545762

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

City of Hope National Medical Center, Duarte
City of Hope National Medical Center, Irvine
Palo Alto Medical Foundation Research Institute (PAMFRI), Palo Alto
și încă 1

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 19 mai 2026 · NCT06588478

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center, Duarte

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 20 apr. 2026 · NCT06859008

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

City of Hope, Duarte
Los Angeles Cancer Network, Los Angeles
UCLA Medical Center of Hematology/Oncology, Los Angeles
și încă 1

În curs de recrutareFaza 1/2

Vârste de la 12 la 95 · Toate sexele · Actualizat 15 apr. 2026 · NCT04329728

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

UCSF FRESNO/Community Cancer Institute /ID# 270874, Clovis
Valkyrie Clinical Trials /ID# 268151, Los Angeles

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 9 apr. 2026 · NCT06428019

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Stanford Cancer Institute Palo Alto, Palo Alto

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 25 mar. 2026 · NCT05388006

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 20 mar. 2026 · NCT04830137

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

City of Hope Medical Center, Duarte
City of Hope at Irvine Lennar, Irvine
City of Hope at Long Beach Elm, Long Beach

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 13 mar. 2026 · NCT07218510

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

City of Hope Medical Center, Duarte

În curs de recrutareFaza 2Voluntari sănătoși bineveniți

Vârste de la 18 la 75 · Toate sexele · Actualizat 10 mar. 2026 · NCT06059391

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Moores Cancer Center at UC San Diego /ID# 230157, La Jolla

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 9 feb. 2026 · NCT04895436

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

UC Irvine Health, Orange

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 10 dec. 2025 · NCT05602363

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

San Francisco VA Medical Center, San Francisco, CA, San Francisco

În curs de recrutareFaza 2

Vârste de la 18 la 80 · Toate sexele · Actualizat 14 oct. 2025 · NCT06520098

Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.